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Abstract  Lung  cancer  is  one  of  the  most  common  cancers  in  the  world  with  a  high  mortality
rate. We  analyzed  45  surgical  samples  of  the  adenocarcinoma,  13  with  lymph  node  metastasis.
APC, BCL2,  chromogranin  A,  CK  5/6/18  (LP34),  CK20,  CK7,  cyclin  D1,  EGFR,  ERCC1,  HER2,  Ki67,
LRP, MRP,  P53,  RB  and  TTF1  expressions  were  evaluated  by  immunohistochemistry  (IHC).
Higher Ki67,  APC,  ERCC1  expressions  and  lower  TTF1  expression  were  identiﬁed  in  advanced
stages (IIA  and  IIIA)  of  adenocarcinomas,  which  reﬂect  a  more  aggressive,  less  differentiated,
possibly  a  non-TRU  adenocarcinoma.
Acinar,  micropapillary  and  BA/lepidic  adenocarcinoma  patterns  were  the  most  similar  pat-
terns and  papillary  was  the  most  different  pattern  followed  by  solid  pattern,  according  to
expression of  these  markers.  Different  adenocarcinoma  patterns  are  engaged  with  differ-
ent molecular  pathways  for  carcinogenesis,  based  on  the  differences  of  expression.  Acinar,
BA/lepidic  and  micropapillary  showed  higher  TTF1  expression  (type  TRU),  and  papillary  and
solid patterns  revealed  less  TTF1  expression,  exhibiting  a  non-TRU/bronchial  phenotype.  Solid
pattern revealed  lower  HER2  and  higher  EGFR  and  ERCC1  (this  compared  to  papillary)  expres-
sion; papillary  higher  HER2  and  lower  ERCC1  expressions;  micropapillary  higher  RB  expression;
and acinar  lower  ERCC1  and  higher  EGFR  expressions.  Ciclin  D1  seems  to  have  more  importance
in acinar  and  BA/lepidic  patterns  than  in  micropapillary.  ERCC1  protein  expression  in  micropap-
illary, solid  and  BA/lepidic  patterns  may  indicate  DNA  repair  activation.  Inhibition  of  apoptosis
could be  explained  by  BCL2  overexpression,  present  in  all  adenocarcinoma  patterns.  MRP-1  and
LRP were  overexpressed  in  all  patterns,  which  may  have  implications  for  drug  resistance.
Further studies  are  needed  to  interpret  these  data  regarding  to  therapy  response  in  advanced
staged bronchial-pulmonary  carcinomas.
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reserved.∗ Corresponding author.
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obacco,  environmental  and  genetic  factors  and  several  lung
iseases  contribute  to  lung  cancer  carcinogenesis.  Lung  can-
er  is  one  of  the  most  common  cancer  diagnosed,  and  has
lso  the  highest  mortality  rate  due  to  the  advanced  stages
t  time  of  diagnosis,  and  when  the  options  for  treatment
ave  to  be  understood  as  personalized  therapy.1--8
Bronchial-pulmonary  carcinomas  consist  of  small  cell  lung
ancer  (SCLC),  squamous  cell  carcinoma  (SCC),  adenocarci-
oma,  large  cell  carcinoma  and  sarcomatoid/pleomorphic
arcinomas.8 Adenocarcinoma  is  the  most  common  type  in
on-smokers  and  its  incidence  has  increased  in  recent  years,
eveloping  after  terminal  respiratory  unit  (TRU)  but  also
ecognized  in  respiratory  epithelium.8--10 Adenocarcinoma
ure  patterns  are  recognized  [acinar,  papillary,  micropapil-
ary,  BA  (bronchioloalveolar/lepidic/AIS-adenocarcinoma  in
itu),  solid  with  mucin  production]  but  mixed  type  pre-
ominates.  Differences  between  the  subtype/patterns  of
denocarcinoma  should  be  taken  into  account  to  improve
iagnosis,  prognosis  and  as  an  enhancement  in  therapy
election.8,10
Cytokeratin  7  (CK7),  high  weight  molecular  cytokeratins
HWMC)  like  CK5/6,  CK20,  chromogranin  A  and  TTF1  are
urrently  used  in  lung  cancer  diagnosis.11,12 Ki67  is  a  cell
roliferation  marker  with  prognostic  value.13--15 In  the  apo-
tosis  pathway,  p53  induces  Bax  transcription  and  reduces
cl2.  Bcl2/Bax  ratio  is  negative  in  lung  carcinomas.16 Inac-
ivation  of  RB  pathway  is  considered  a  requirement  for
ung  carcinogenesis.16 Adenomatous  polyposis  coli  (APC)
ene  is  involved  in  the  canonical  Wnt/-catenin  signal
ransduction.  APC  is  mutated  in  liver,  colorectal  adeno-
as  and  lung  tumors.17 Cyclins  D  (D1,  D2,  and  D3)  are
ctivators  of  cyclin-dependent  kinases  cdk4  and  cdk6,  to
ranslate  growth  signals  into  cell  cycle  progression,  lead-
ng  to  proliferation.18,19 Cyclin  D1  overexpression  and  pRB
nactivation  indicates  a  poor  prognosis.20
Bcl2  as  an  anti-apoptotic  protein  has  a  more  impor-
ant  role  in  neuroendocrine  (NE)  lung  cancer  than
n  other  bronchial-pulmonary  carcinomas.21 Excision
epair  cross-complementing  1  (ERCC1)  genetic  polymor-
hisms  may  affect  patient’s  response  to  platinum-based
hemotherapy.22,23 However,  another  study  concluded  that
atients  with  a  bronchial-pulmonary  carcinoma  with  high
RCC1  expression  have  a  better  prognosis  than  those  with
ow  expression.24 Multidrug  Resistance  Protein  1  (MRP-1)
nd  lung  resistance-related  protein  (LRP)  may  confer
esistance  to  cytotoxic  and  antiviral  drugs.25--31
EGFR  and  HER2  play  a  central  role  in  tumorigenesis.32,33
argeting  those  receptors  provides  a  unique  approach  for
reating  EGFR/HER2  expressing  cancers.34,35 The  most  com-
on  alteration  of  HER2  is  overexpression/ampliﬁcation;
utations  are  less  frequent.33,35,36 The  activated  receptors
rigger  Ras-Raf-MEK  (mitogen-activated  and  extracellular
ignal  regulated  kinase),  ERK1  and  ERK2  (extracellular-signal
egulated  kinase  1  and  2)  pathways  leading  to  cell  growth,
TOR  (mammalian  target  of  rapamycin)  pathway  leading
o  protein  synthesis,  and  PI3K-AKT  (phosphatidylnositol-2
inase  Akt)  pathway  sustaining  cell  survival.36
The  objectives  of  this  work  were  to  validate  a  small
ifferentiation  IHC  panel,  evaluate  protein  expression  of
i
w
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ifferent  genes  according  to  different  adenocarcinoma  pat-
erns,  and  correlate  this  expression  with  cell  pathways
f  progression  and  drug  resistance,  in  order  to  under-
tand  bronchial-pulmonary  adenocarcinoma  carcinogenesis.
nother  objective  was  to  verify  possible  differences  of  gene
xpression  in  adenocarcinoma  taking  into  account  variables
uch  as  gender,  age,  smoking  and  different  tumor  stages.
he  global  intention  of  this  project  is  to  acquire  knowl-
dge  which  can  be  applied  in  the  diagnosis  and  prognosis
valuation  of  bronchial-pulmonary  adenocarcinoma  and  its
ubtypes  in  order  to  deﬁne  individual  treatment.
aterials and methods
aterials
urgical  samples  of  bronchial-pulmonary  adenocarcinomas
n  = 45)  covering  all  subtypes  recognized  by  WHO/2004  were
andomly  selected  and  staged  by  the  2010  TNM  system;  the
RS/ATS  proposal  was  also  applied.  At  least  two  sections
f  each  tumor  and  sections  of  lymph  node  metastasis  were
elected  (Table  1).12,37
ethods
K7,  TTF1,  CK20,  CK  5/6/18  (LP34),  chromogranin  A,
i67,  P53,  RB,  BCL2,  cyclin  D1,  APC,  ERCC1,  LRP,  MRP-1,
GFR,  and  HER2  expressions  were  evaluated  by  immuno-
istochemistry  (IHC).  IHC  was  performed  on  formalin-ﬁxed,
arafﬁn-embedded  tissue  samples  in  automatic  immunos-
ainer  (Autostainer  360  --  LabVision®).  Streptavidin  biotin
rotocol  was  applied  according  to  the  manufactures  indica-
ions  for  each  antibody.  Three-micrometer  tissue  sections
ere  placed  on  coated  slides  and  allowed  to  dry  overnight.
fter  deparafﬁnization  and  rehydration,  antigen  retrieval
as  performed  according  to  Table  2. Endogenous  peroxi-
ase  activity  was  quenched  using  15  min  incubation  in  3%
iluted  hydrogen  peroxide  (H2O2).  For  blocking  non-speciﬁc
inding,  Ultra  V  Block  (Ultra  Vision  Kit®;  TP-015-HL)  was
pplied  to  the  sections  and  then  they  were  incubated
t  room  temperature,  with  primary  antibodies  according
o  Table  2.  After  washing  with  phosphate-buffered  saline
PBS),  slides  were  incubated  with  biotin-labeled  secondary
ntibody  (LabVision®) for  15  min.  Primary  antibody  bind-
ng  was  localized  in  tissues  using  peroxidase-conjugated
treptavidin  (LabVision®) and  3,3-diaminobenzidine  tetrahy-
rochloride  (DAB)  was  used  as  the  chromogen,  according  to
anufacturer’s  instructions.  The  slides  were  counterstained
ith  hematoxylin,  dehydrated  and  mounted.  In  parallel,
nown  positive  (Table  2) and  negative  controls  were  used.
Three-micrometer  tissue  sections  were  placed  on  coated
lides  and  allowed  to  dry  overnight.  IHC  scoring  was  applied
ndependently  by  two  pathologists  who  registered  the
ntensity  of  expression  (1  --  low  expression,  2  --  interme-
iate  expression  and  3  --  high  expression)  and  percentage
f  stained  cells.  For  statistical  analyses  we  grouped  the
mmunohistochemistry  results  in  4  categories.  For  each  case
e  multiplied  the  intensity  of  expression  by  the  percentage
f  staining  cells  and  we  used  this  score  for  the  formation  of
Bronchial-pulmonary  adenocarcinoma  subtyping  261
Table  1  Gender  (M  --  male;  F  --  female),  age,  smoking  status,  TNM  classiﬁcation,  stage  and  patterns  present  (A  --  acinar;  B  --
BA/lepidic; C  --  papillary;  D  --  micropapillary  and  E  --  solid).
Gender  Age  Tobacco  TNM  Stage  Patterns
1  M  73  Non-smoker  pT1aN0Mx  IA  A;  B
2 F  71  Non-smoker  pT1aN0Mx  IA  A;  B
3 M  69  Smoker  pT4N0Mx  IIIA  A;  B;  C
4 M  75  Non-smoker  pT1aN2Mx  IIIA  A;  E
5 F  53  Non-smoker  pT1aN0Mx  IA  A;  B
6 M  76  Ex-smoker  pT2bN0Mx  IIA  A;  B;  E
7 F  62  Ex-smoker  pT1aN2Mx  IIIA  A;  B;  E
8 F  74  Non-smoker  pT1aN0Mx  IA  A;  B;  E
9 F  68  Non-smoker  pT2aN0Mx  IB  A;  D;  E
10 F  50  Non-smoker  pT1bN2Mx  IIIA  A;  E
11 F  57  Smoker  pT2aN0Mx  IB  A;  E
12 M  51  Non-smoker  pT1aN1Mx  IIA  A;  B
13 F  75  Non-smoker  pT2aN0Mx  IB  A;  D;  E
14 M  85  Ex-smoker  pT1aN0Mx  IA  A;  B
15 F  63  Smoker  pT2aN0Mx  IB  A;  B;  D
16 F  55  Smoker  pT1aN0Mx  IA  A;  E
17 F  67  Smoker  pT1aN0Mx  IA  A;  B;  D
18 M  48  Smoker  pT1aN0Mx  IA  A;  B;  E
19 M  71  Non-smoker  pT2aN1Mx  IIA  A;  D
20 M  49  Smoker  pT2aN0Mx  IB  A
21 F  80  Non-smoker  pT1bN0Mx  IA  A;  D
22 F  68  Non-smoker  pT2aN1Mx  IIA  A;  D
23 M  48  Non-smoker  pT2bN0Mx  IIA  A;  B
24 F  67  Non-smoker  pT2aN0Mx  IB  A
25 M  76  Ex-smoker  pT1bN0Mx  IA  A;  B
26 F  56  Non-smoker  pT1aN0Mx  IA  A;  B;  C;  D
27 M  64  Smoker  pT2bN0Mx  IIA  A;  C
28 F  71  Non-smoker  pT2aN0Mx  IB  A;  B;  E
29 F  50  Smoker  pT2aN0Mx  IB  B;  E
30 F  80  Non-smoker  pT1aNxMx  IA  E
31 M  56  Smoker  pT1aN0Mx  IA  A;  B
32 F  56  Non-smoker  pT1aN0Mx  IA  A;  B
33 F  54  Non-smoker  pT1aN0Mx  IA  B
34 M  67  Smoker  pT2aN1Mx  IIA  A;  E
35 F  62  Non-smoker  pT1bN1Mx  IIA  A;  C;  D
36 F  68  Non-smoker  pT1bN0Mx  IA  A;  B
37 F  44  Non-smoker  pT2bN2Mx  IIIA  A;  E
38 F  52  Smoker  pT3N1Mx  IIIA  A;  B;  D
39 M  45  Smoker  pT2aN1Mx  IIA  A;  C
40 M  61  Smoker  pT2aN0Mx  IB  A
41 F  74  Non-smoker  pT2aN0Mx  IB  A;  D
42 F  74  Non-smoker  pT2aN0Mx  IB  A;  B
43 M  73  Non-smoker  pT2aN1Mx  IIA  A;  B
44 F  60  Non-smoker  pT1bN0Mx  IA  A;  B;  D
45 F  79  Non-smoker  pT2aN0Mx  IB  A;  B;  D
R
P
a
neach  category  (category  (−)  0--10;  (+)  11--100;  (++)  101--200;
(+++)  201--300)  (Table  3)
The  non-parametric  Wilcoxon-Mann--Whitney  test  was
used  to  analyze  the  differences  between  categories.  Hier-
archical  clustering  and  Principal  Component  Analysis  (PCA)
was  made  to  validate  relationships  between  patterns.  We
used  the  software  STASTISTICA  7.  P  values  less  than  0.05
were  considered  signiﬁcant.
a
s
(esults
redominantly  mixed-type  adenocarcinomas,40 three  acinar
denocarcinomas,  one  solid  mucin  producing  adenocarci-
oma  and  one  bronchioloalveolar  (BA)/lepidic  mucinous
denocarcinoma/mucinous  adenocarcinoma  in  situ  were
tudied  to  validate  the  different  patterns.  Forty-two  cases
93.3%)  with  acinar  pattern  (being  the  most  prevalent),
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Table  2  Antibodies  applied  antigen  retrieval,  dilution  and  incubation  time  and  staining  patterns.  RT  --  room  temperature.
Primary  antibody  Manufacture  Clone  Positive  control  Antigen
retrieval
Dilution  and
incubation  time
Staining
pattern
APC  Novocastra  EMM43  Colon  PT  module,
EDTA
1:40,  60′ Membrane  and
cytoplasmic
Bcl2 Novocastra  3.1  Tonsil  PT  module,
EDTA
1:150,  60′ Membrane  and
cytoplasmic
Chromogranin A  DAKO  DAK-A3  Carcinoid  tumor  PT  module,
citrate
1:200,  30′ Cytoplasmic
CK (5/6/18)  Novocastra  LP34  Lung  Pronase  E  (10′,
RT)
1:100,  60′ Cytoplasmic
CK20 DAKO  KS20.8  Colon  Pronase  E  (10′,
RT)
1:50,  30′ Cytoplasmic
CK7 DAKO  KS20.8  Lung  Pronase  E  (10′,
RT)
1:50,  30′ Cytoplasmic
Cyclin D1  Novocastra  P2D11F11  Breast  carcinoma  PT  module,
EDTA
1:30,  60′ Nuclear
EGFR Zymed  31G7  Respiratory  epithelia  Pronase  E  (10′,
RT)
1:20,  30′ Membrane  and
cytoplasmic
ERCC1 Thermo  8F1  Tonsil  PT  module,
EDTA
1:100,  60′ Nuclear
HER2 DAKO  Polyclonal  Breast  carcinoma  PT  module,
citrate
1:200,  30′ Membrane
Ki67 DAKO  MIB-1  Small  cell  carcinoma  PT  module,
citrate
1:50,  30′ Nuclear  except
mitotic  cells
LRP Novocastra  9D6  Ileon  PT  module,
EDTA
1:300,  30′ Cytoplasmic
MRP-1 Novocastra  33A6  Colon  PT  module,
citrate
1:50,  60′ Cytoplasmic
P53 DAKO  DO-7  Skin  PT  module,
citrate
1:50,  30′ Nuclear  and
cytoplasmic
RB Novocastra  13A10  Tonsil  PT  module,
EDTA
1:50,  60′ Nuclear
TTF1 DAKO  8G7G3/1  Small  cell  carcinoma  PT  module, 1:100,  60′ Nuclear
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s6  (57.8%)  with  BA/lepidic  pattern,  15  (33.3%)  with  solid
attern,  5  (11.1%)  with  papillary  and  15  (33.3%)  with
icropapillary  pattern  were  registered.
Thirteen  cases  (28.9%)  showed  lymph  node  metastasis
s  follows:  acinar  pattern  was  present  in  13  cases  (100%);
olid  and  micropapillary  patterns  were  present  in  3  cases
ach  (23%);  and  papillary  pattern  in  2  cases  (15.4%).  Two
etastasis  with  solid  pattern  belonged  to  primary  adenocar-
inomas  which  harbored,  respectively,  acinar  and  BA/lepidic
nd  acinar,  BA/lepidic  and  micropapillary  patterns.
Seventeen  cases  (37.8%)  were  diagnosed  in  men  and
wenty-eight  cases  (62.2%)  in  women.  Age  at  diagnosis
anged  from  44  to  85  years  with  a  median  of  67  years.
ourteen  cases  (31.1%)  were  diagnosed  in  smokers  (8  males
nd  6 females),  four  (8.9%)  in  ex-smokers  (3  males  and  1
emale)  and  twenty-seven  (60%)  in  never  smokers  (6  males
nd  21  females).  Female  patients  were  more  frequently  non-
mokers  than  men  (p  =  0.0251).
Seventeen  cases  (37.8%)  were  diagnosed  as  stage  IA
5  males/12  females),  twelve  (26.7%)  as  IB  (2  males/10
emales),  ten  (22.2%)  as  IIA  (8  males/2  females)  and  six
13.3%)  as  stage  IIIA  (2  males/4  females).  Females  were
a
w
pEDTA
iagnosed  more  frequently  in  lower  stages  when  compared
o  men  (p  =  0.029).  There  were  no  differences  between
tages  according  to  smoking  habits.
All  adenocarcinomas  (n  =  45)  expressed  CK7.  No  expres-
ion  was  observed  for  CK20,  HWMC  or  chromogranin  A.  TTF1
as  expressed  in  the  great  majority  of  lung  adenocarcino-
as,  with  statistical  signiﬁcant  higher  expression  in  acinar
attern  (p  =  0.0094),  micropapillary  pattern  (p  =  0.012)  and
A/lepidic  patterns  (p  =  0.00046).  The  expression  was  signif-
cantly  higher  in  BA/lepidic  pattern  when  compared  to  solid
attern  (p  =  0.021).
Nuclear  expression  of  P53  was  statistically  higher  in  all
atterns  when  compared  to  normal  tissue  (p  < 0.05),  without
ifferences  between  patterns.
RB  expression  was  higher  in  micropapillary  pattern  when
ompared  to  normal  tissue  (p  =  0.011).  The  other  patterns
howed  no  differences  from  basal  expression  in  normal  tis-
ue.
There  were  no  signiﬁcant  differences  between  primary
denocarcinomas  and  their  metastasis,  except  for  cyclin  D1
hose  expression  was  higher  in  the  metastasis  when  com-
ared  to  the  primary  neoplasia  (p  =  0.0409).
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Table  3  TTF1,  KI67,  P53,  RB,  APC,  BCL2,  Ciclin  D1,  ERCC1,  MRP1,  LRP,  HER2  and  EGFR  expression  according  to  adenocarcinoma
pattern. A  --  acinar;  B  --  BA/lepidic;  C  --  papillary;  D  --  micropapillary  and  E  --  solid  patterns.  Expression  categories:  0  =  (−)  =  0--10%;
1 =  (+)  =  11--100%;  2  =  (++)  =  101--200%;  3  =  (+++)  =  201--300%.
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sAPC  expression  was  higher  in  all  patterns  when  compared
to  normal  tissues  (p  <  0.05),  with  no  differences  between
patterns.
BCL2  expression  was  higher  in  all  patterns  studied
than  normal  adjacent  tissue  (p  <  0.05),  without  differences
between  patterns.
Cyclin  D1  expression  differed  between  normal  tissue  and
solid  (p  =  0.0002)  and  BA/lepidic  (p  =  0.002)  patterns,  being
higher  in  these  patterns  than  in  the  normal  tissue.
EGFR  protein  expression  was  higher  in  acinar  (p  =  0.033)
and  solid  (p  =  0.012)  patterns  when  compared  to  normal
tissues,  concerning  membrane  expression  only.  If  we  take
into  account  cytoplasmic  expression  the  overall  expression
was  signiﬁcantly  higher  in  all  patterns  without  differences
between  them.
For  HER2  we  observed  signiﬁcantly  higher  expression  in
all  patterns  compared  to  normal  tissue  (p  <  0.05).  Expres-
sion  is  also  higher  in  acinar,  papillary,  micropapillary  and
BA/lepidic  patterns  compared  to  solid  pattern  (p  <  0.05).
ERCC1  expression  was  lower  in  acinar  (p  =  0.0016)  and
papillary  (p  =  0.019)  patterns  compared  to  normal  tissue.
Expression  in  the  other  patterns  revealed  no  differences  to
basal  expression  in  normal  tissue.  Papillary  pattern  has  sig-
niﬁcant  less  expression  than  solid  (p  <  0.05)  and  BA/lepidic
patterns  (p  <  0.05).
(
a
nKi67  expression  was  higher  in  all  adenocarcinoma  pat-
erns  when  compared  to  normal  lung  tissue  (p  <  0.05).  There
ere  no  differences  between  the  patterns.
LRP  expression  was  different  (higher)  between  nor-
al  and  the  different  patterns  of  the  adenocarcinomas
p  <  0.05).
MRP-1  expression  was  higher  in  all  patterns  compared  to
ormal  lung  tissue,  without  differences  between  patterns
p  <  0.05).
Some  immunohistochemical  results  are  illustrated  in
ig.  1.
The  analysis  of  the  dendrogram  clearly  showed  that  ade-
ocarcinoma  is  genetically  different  from  normal  tissue
Fig.  2).  Concerning  the  patterns,  BA/lepidic  and  acinar  are
he  more  similar  and  papillary  the  most  distinct  or  genet-
cally  separated  pattern.  By  PCA  analysis  (Fig.  3) we  were
ble  to  identify  three  clusters:  the  ﬁrst  composed  of  papil-
ary  pattern  adenocarcinomas;  the  second  corresponding  to
olid;  and  the  third  to  the  group  of  acinar,  BA/lepidic  and
icropapillary  patterns.
Looking  at  gender,  we  have  identiﬁed  higher  expres-
ion  of  ERCC1  in  female  patients  when  compared  to  males
p  =  0.0008).  We  did  not  ﬁnd  any  differences  according  to
ge.  HER2  expression  was  higher  in  adenocarcinomas  of
on-smokers  or  ex-smokers  (p  =  0.0384).  Ki67  expression
264  V.  Sousa  et  al.
Figure  1  (A)  Expression  (++)  of  APC  in  BA  pattern,  200×; (B)  Expression  (+++)  of  BCL2  in  papillary  pattern,  200×;  (C)  BA  pattern
with Cyclin  D1  expression,  400×; (D)  Cyclin  D1  expression  in  solid  pattern,  200×;  (E)  EGFR  expression  (+++)  in  acinar  pattern,  200×;
(F) EGFR  expression  (+++)  in  solid  pattern,  200×;  (G)  ERCC1  expression  (++)  in  BA  pattern,  200×; (H)  ERCC1  expression  (++)  in  solid
pattern, 200×; (I)  HER2  expression  (++)  in  acinar  pattern,  400×; (J)  Ki67  expression  (+++)  in  lymph  node  metastasis,  200×; (L)  Ki67
expression (+++)  in  acinar  pattern,  400×;  (M)  LRP  expression  (+++)  in  acinar  pattern,  400×; (N)  MRP-1  expression  (+++)  in  solid
pattern, 200x;  (O)  RB  expression  (++)  in  papillary  pattern,  200×; and  (P)  P53  expression  (+++)  in  micropapillary  pattern,  200×.
Bronchial-pulmonary  adenocarcinoma  subtyping  
Tree diagram for 6 variables
single linkage
euclidean distances
Normal
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Figure  2  Dendrogram  for  the  hierarchical  clustering  analysis
of transcripts  according  to  their  expression  values,  using  Single
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rlinkage  algorithm,  Euclidean  distances,  targeting  the  various
patterns  and  normal  tissue.
was  higher  in  adenocarcinomas  of  smokers  and  ex-smoker
patients  (p  =  0.0034  and  p  =  0.0064).
TTF1,  Ki67,  APC,  RB,  P53,  BCL2,  ERCC1  and  EGFR  showed
signiﬁcantly  different  expressions  according  to  the  stage  of
the  tumor.  TTF1  expression  showed  differences  between
stage  IA  and  IIIA,  being  higher  in  stage  IA  (p  = 0.02).  Ki67
was  higher  in  IIIA  compared  to  IA  and  IIA  (p  =  0.02  and
p  =  0.02).  APC  expression  was  higher  in  IIA  and  IIIA  com-
pared  to  IA  (p  =  0.065  and  p  =  0.025).  RB  expression  was
higher  in  stage  IB  tumors  compared  to  stage  IA  (p  = 0.04).
P53  expression  was  higher  in  IIA,  IB  and  IIIA  compared  to  IA
(p  =  0.01;  p  =  0.03;  p  =  0.01).  BCL2  expression  was  higher  for
IB  compared  to  IA  (p  =  0.039).  ERCC1  was  higher  in  stage
IA  compared  to  IIA  (p  =  0.02)  and  in  IIIA  compared  to  IIA
BAC
Projection of the variables on the factor-plane (1 x 2)
Papillary
Acinar
 Solid
1.0
0.5
0.0
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Figure  3  The  correlation  of  the  patterns  with  the  advanced
PCA factor  analysis.
s
c
m
i
a
b
B
l
f
B
m
M
C
s
p
c
r
l
i
g
T
a
u
o
b
a265
p  =  0.01).  EGFR  expression  was  lower  in  stage  IB  compared
o  IA  (p  =  0.032).
To  sum  up,  almost  all  patterns  showed  differences  of
xpression  in  relation  to  normal  tissues  with  some  excep-
ions  for  cyclin  D1  (papillary  and  micropapillary  patterns),
or  EGFR  membrane  staining  (papillary  and  micropapil-
ary  patterns),  for  ERCC1  (in  micropapillary,  solid  and
A/lepidic  patterns),  for  RB  (in  acinar,  papillary  and
olid  patterns)  and  for  TTF1  (in  papillary  and  solid  pat-
erns).
Solid  pattern  demonstrated  lower  HER2  expression  com-
ared  to  acinar,  papillary,  micropapillary  and  BA/lepidic
atterns.  Papillary  pattern  had  lower  ERCC1  expression  than
olid  and  BA/lepidic  patterns.  Solid  pattern  showed  lower
TF1  expression  than  BA/lepidic  pattern.
iscussion
on-BA/lepidic  adenocarcinomas  are  most  often  periph-
ral  tumors  with  different  growth  patterns  considered
ixed  type  according  to  WHO  classiﬁcation,  with  at
east  two  individual  patterns;  solid  or  acinar  patterns
re  the  most  frequent  in  the  central  tumoral  bulk  and
A/lepidic  at  the  periphery.  Acinar  has  been  described
s  the  most  common  pure  subtype  and  the  most  com-
on  in  the  mixed  type.  Papillary  pattern  was  present  in
0%  of  the  adenocarcinomas,  often  difﬁcult  to  differen-
iate  from  BA/lepidic,  which  has  important  therapeutic
trategies’  implications.9 Micropapillary  pattern  is  cha-
acterized  by  small  papillary  tufts  growing  from  alveolar
epta  or  ﬂoating  within  alveolar  spaces  lacking  ﬁbrovas-
ular  cores  and  is  usually  observed  with  papillary  and
ixed  patterns;  they  are  more  aggressive  due  to  their
ncreased  capacity  for  metastasize,  indicating  unfavor-
ble  prognosis.9 Solid  pattern  with  mucin  production  has
een  reported  in  15%  of  mixed-type  adenocarcinomas.9,10
A/lepidic  pattern  shows  tumor  cell  growth  along  alveo-
ar  septa  and  aerogeneous  spread  through  the  lung.  It  is
requently  diagnosed  in  former  and  non-smoking  women.
A/lepidic  is  classiﬁed  as  non-mucinous,  mucinous  or
ixed.9,10,38
arkers  of  differentiation
K20,  HWMC  and  chromogranin  A  were  negative  in  all  our
amples  and  CK7  and  TTF1  were  positive,  which  means  mor-
hology  almost  always  sustains  bronchial-pulmonary  adeno-
arcinomas’  diagnosis  when  mucin  is  not  present.  These
esults  corroborated  those  that  have  been  described  in  the
iterature.  CK7  is  positive  in  90--100%  and  CK20  is  positive
n  only  7--10%  of  primary  lung  adenocarcinomas.39 Chromo-
ranin  A  is  not  expressed  in  an  ordinary  adenocarcinoma.40
TF1  is  a  useful  marker  for  lung  adenocarcinoma  and  is
lso  expressed  in  thyroid  normal  tissue  and  tumors.22 The
se  of  TTF1,  as  a  differentiation  marker,  is  useful  not
nly  for  diagnostic  purpose  but  especially  to  differentiate
etween  different  histological  types  of  bronchial  and  TRU
denocarcinomas.
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enetic  expression  in  each  pattern  of
ronchial-pulmonary  adenocarcinoma
cinar  pattern
tarting  with  membrane  proteins  that  play  a  central  role
n  the  control  of  cellular  proliferation,  differentiation,
poptosis  and  angiogenesis,  EGFR  and  HER2  had  a  higher
xpression  in  acinar  pattern  than  in  normal  epithelium/lung
ells,  highlighting  the  importance  of  AKT/mTOR,  PI3K  and
APK  pathways,  essential  for  oncogenic  transformation  and
umor  maintenance.41 Blockage  of  both  results  in  apoptosis
nd  tumor  shrinkage.42,43 AKT,  by  inhibiting  GSK-3,  changes
anonical  Wnt  pathway,  releasing  -catenin,  and  leading  to
ngiogenesis  and  proliferation.44
TTF1  positivity  was  statistically  higher  in  the  adenocar-
inomas  (with  acinar  pattern)  compared  to  normal  tissue.
hile  the  majority  of  the  adenocarcinomas  expresses  TTF1,
his  marker  is  misunderstood,  because  its  positivity  is  associ-
ted  inversely  with  proliferation  but  it  is  correlated  with  P53
xpression  and  HER2/neu  involved  in  lung  cancer.45 TTF1,
KX2-8  and  PAX9  are  very  important  in  initiation  and  pro-
ression  of  lung  cancer.  It  is  said  that  MAPKinase,  JAK/STAT
nd  Wnt  are  important  in  activation  of  TTF1  and  NKX8,  con-
ected  with  EGFR  and  Her2.46
The  expression  of  cyclin  D1  was  higher  in  tumoral  than
n  normal  tissue  and  RB  expression  had  no  statistical  dif-
erence  when  compared  to  normal  tissue.  This  fact  may
ndicate  a  tendency  to  proliferate,  because  once  cyclin  D1  is
n  high  concentration,  it  could  phosphorylate  more  RB  pro-
ein  and  release  E2F,  involved  in  the  regulation  of  genes  with
mplications  in  cell  cycle  progression  (G1  to  S  phase).43,47
ne  of  the  genes  that  correlate  with  E2F  is  Ki67,  still  a
ood  marker  for  proliferative  index.48 We  obtained  statis-
ical  signiﬁcant  higher  expression  of  Ki67  in  all  patterns  of
denocarcinoma,  indicating  active  proliferative  activity.49
nother  overexpressed  gene  in  this  pattern  was  P53  and
ome  studies  indicate  that  ‘‘a  low  level  of  p53  leads  to
ransient  growth  arrest  and  cell  survival,  whereas  a  high
evel  promotes  irreversible  apoptosis’’,  and  P53  levels  may
ave  oscillations,  and  it  has  to  be  explored  as  a  target  for
herapy.50 ERCC1  is  downregulated  in  acinar  pattern,  may  be
ndicating  that  DNA  repair  pathway  is  not  activated  in  the
cinar  pattern.  ERCC1  is  associated  with  radio  resistance,  so
t  is  important  for  treatment  choice.51 High  BCL2  expression
ay  favor  cell  cycle  arrest.
LRP  and  MRP1  were  also  overexpressed  in  our  samples,  as
as  been  described  in  lung  cancer.52,53 As  mentioned  these
enes  can  lead  to  chemotherapy  resistance.  This  fact  should
e  taken  into  consideration  when  assessing  prognosis  and
reatment  issues.
APC  was  also  overexpressed  in  the  acinar  pattern,
nd  being  involved  in  -catenin  degradation  is  important
n  progression,  with  GSK-3 and  Axin  downregulating  -
atenin  (leading  to  -catenin  degradation).54 Our  ﬁndings
lso  suggest  that  -catenin  may  be  downregulated,  already
escribed  in  lung  cancer,  which  is  related  to  cell  invasion
nd  metastasis.55 -Catenin  is  connected  to  cytoskeleton
nd  cadherins  and  regulates  E-  or  N-cadherin-mediated
ell  adhesion.  Notch  activation  (that  inactivates  -catenin)
ay  repress  E-cadherin,  leading  to  tumor  growth  and
etastasis.56 So,  overexpression  of  APC  leads  to  -catenin
e
b
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egradation  that  weakens  cell  adhesion  promoting  tumor
rowth  and  metastasis.
In  relation  to  the  acinar  pattern  the  genes  analyzed
xpressions  could  lead  to  cell  proliferation  and  survival,
ngiogenesis  and  metastasis.
apillary  pattern
his  pattern  showed  some  differences  compared  to  acinar
attern.  There  were  no  differences  of  expression  for  cyclin
1  and  TTF1,  compared  with  normal  tissue.  Since  cyclin  D1
evel  is  not  upregulated  as  well  as  RB  gene,  the  concen-
ration  of  active  E2F  must  be  regular.  However  Ki67  was
verexpressed,  in  contrast  to  previous  ﬁndings.21 So  other
athways  could  explain  cellular  proliferation.  There  was
igher  expression  of  EGFR  but  just  in  cytosol  compartment;
embrane  EGFR  had  the  same  level  of  expression  as  normal
issue,  so  we  can  conclude  that  activity  of  EGFR  is  normal.
hus,  all  pathways  that  this  gene  regulates  are  functioning
ormally  or  if  activated,  this  activation  is  not  induced  by
GFR.41,57,58
Papillary  pattern  proliferation  properties  could  in  part  be
xplained  by  APC  upregulation  when  compared  to  normal
issue.
icropapillary  pattern
icropapillary  pattern  is  characterized  by  small  papillary
ufts  and  is  considered  an  aggressive  adenocarcinoma,  more
han  papillary  pattern.59--61 There  were  three  differences
ith  papillary  patterns  concerning  expression  of  ERCC1,  RB
nd  TTF1.  RB  expression  was  downregulated  in  micropap-
llary,  being  almost  non-existent.  Some  authors  said  that
ownregulation  of  RB  leads  to  the  progression  of  cell  cycle.62
icropapillary  pattern  had  a  basal  level  of  ERCC1,  this  indi-
ating  that  DNA  repair  may  occur  with  NER  activation.  TTF1
as  overexpressed  in  this  pattern  and,  according  with  what
as  been  said  before,  this  fact  indicates  lung  cancer  progres-
ion  and  development  after  the  terminal  respiratory  unit.
hese  considerations  are  consistent  with  our  results  because
ownregulation  of  RB  and  TTF1  overexpression  are  responsi-
le  for  cell  cycle  progression  and  basal  level  of  ERCC1  allows
NA  repair.  This  last  consideration  is  very  important  to  keep
n  mind  in  treating  lung  cancer.
olid  pattern
enetic  expression  in  this  pattern  is  identical  to  acinar
attern  with  only  two  differences  for  ERCC1  and  TTF1
xpressions.  These  showed  no  differences  compared  to  nor-
al  tissue  in  solid  pattern,  whereas  in  acinar  pattern  there
as  a higher  expression  for  TTF1  and  downregulation  for
RCC1.  A  lower  TTF1  expression  reﬂects  a lower  differenti-
tion  of  this  pattern  and  eventually  means  a  more  aggressive
ehavior  since  in  general  less  differentiated  tumors  are
ore  aggressive.  Higher  EGFR  expression  could  be  the  reﬂex
f  EGFR  mutations  and/or  overexpression  activating  sev-
ral  pathways  involved  in  cell  cycle  control,  proliferation
nd  even  metastization.  EGFR  overexpression  is  also  associ-
ted  with  poor  prognosis.33,63 Solid  pattern  has  more  ERCC1
xpression  than  acinar  and  this  aspect  is  very  important
ecause  ERCC1  repairs  DNA  and  confers  resistance  to  some
rugs.51
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BBronchial-pulmonary  adenocarcinoma  subtyping  
BA/lepidic  pattern
BA  pattern,  called  lepidic  in  ATS/ERS  proposed  classiﬁcation
can  be  difﬁcult  to  distinguish  morphologically  from  papil-
lary  pattern.12 Cyclin  D1  had  higher  expression  in  BA/lepidic
pattern  and  a  basal  level  in  papillary  pattern.  This  fact
and  knowing  that  RB  was  not  overexpressed,  enhances  the
idea  that  this  pathway  leads  to  cell  progression.  As  TTF1
is  related  with  tumor  progression  and  is  overexpressed,
unlike  in  papillary  pattern,  and  ERCC1  has  a  basal  level  in
BA/lepidic  pattern  and  is  downregulated  in  papillary  pat-
tern,  this  may  explain  chemical  resistance.
By  evaluating  the  expression  of  these  13  genes,
BA/lepidic  pattern  has  more  cell  progression  pathways
activated  than  papillary  pattern.  This  ﬁnding  proves  that
they  are  biologically  different.  The  differences  could  be
explained  by  the  origin  in  TRU  with  the  different  activated
pathways,  with  probable  implication  in  the  prognosis  and
treatment,  knowing  that  different  pathways  are  targets  for
therapeutic  approach.
Metastasis  analysis
Metastasis  formation  is  a  complex  process  with  several  path-
ways  activated  leading  to  loss  of  cellular  adhesion,  increased
motility  and  invasiveness.55 Acinar  pattern  metastasis  had
cyclin  D1  over-expression,  statistically  different  between
primary  and  metastatic  tumor.  This  gene  is  involved  in  cell
progression  that  might  be  helping  cell  survival  in  circulation
and  colonization.55
Gender,  age,  smoking  and  tumor  staging
ERCC1  expression  was  higher  in  females,  correlating  in  some
studies  to  a  better  prognosis.64 However  ERCC1  may  confer
resistance  to  cisplatin.65
Lung  adenocarcinoma  is  more  frequently  diagnosed  in
patients  over  60  years  and  it  is  infrequent  before  age  40
and  generally  more  aggressive.66 All  our  samples  were  taken
from  patients  older  than  the  age  of  40.  There  were  no  dif-
ference  in  the  expression  of  the  markers  studied  between
the  group  under  and  over  60  years.
Concerning  smoking  history,  HER2  expression  was  higher
in  non-smokers  than  in  ex-smokers.  Ki67  expression  was
higher  in  tumors  of  smokers  and  ex-smoker  patients  than
in  non-smokers,  indicating  a  higher  proliferative  rate  and
more  aggressive/mitotically  active  tumors.
Women  diagnosed  with  adenocarcinoma  were  more  fre-
quently  non-smokers,  reﬂecting  the  cultural  tobacco  habits
and  some  of  those  adenocarcinomas  belonging  to  the  group
of  adenocarcinomas  diagnosed  in  women,  non-smokers  and
young  that  could  harbor  EGFR  mutations.67 Adenocarcino-
mas  diagnosed  in  women  patients  were  more  frequently
diagnosed  at  stages  IA  and  IB  reﬂecting  somehow  a less
aggressive  behavior  demonstrated  also  by  a  lower  prolifera-
tive  index  in  these  stages.  Tobacco  habits  could  also  explain
the  activation  of  different  pathways  and  genetic  alterations
in  these  cases.  Our  results  also  demonstrated  a  relation
between  higher  Ki67  expression  and  smoking  habits.
Many  gene  products  have  their  expression  altered  when
correlating  with  stage,  such  as  APC,  BCL2,  EGFR,  ERCC1,
Ki67,  P53,  RB  and  TTF1,  showing  that  gene  expression  is  a
s
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ynamic  and  unforeseen  process.  From  stage  IA  to  IB  we
bserved  lower  Bcl2  and  EGFR  expressions  and  RB  higher
xpression.  From  stage  IB  to  IIA  we  observed  higher  Bcl2  and
ower  ERCC1  expressions.  IIIA  stage  showed  higher  ERCC1
nd  Ki67  expressions.  From  IA  and  IB  to  IIA  we  observed
lso  higher  APC  and  Bcl2  expressions.  In  advanced  stages
e  observed  especially  higher  Ki67,  APC  and  ERCC1  expres-
ions  and  lower  TTF1  expression,  the  last  reﬂecting  a  lower
ifferentiation  and  even  a  non-TRU  adenocarcinoma  with  a
ore  aggressive  behavior.  Ki67  higher  expression  in  higher
tages  was  an  expected  result  as  it  reﬂects  higher  prolif-
ration  index  and  thus  aggressive  behavior.  APC  mutations
ere  described  in  several  tumors.17 Taking  into  account  our
esults,  it  seems  that  APC  genetic  and  pathways  changes  are
mportant  to  consider  in  advanced  stages  of  adenocarcino-
as.
One  of  the  most  important  molecule  in  this  study  was
53  because  it  was  higher  expressed  in  all  patterns  and  is
nvolved  in  several  pathways  and  mechanisms  in  normal  cell
ycle,  carcinogenesis  and  DNA  repair  with  obvious  thera-
eutic  implications.  Some  authors  relate  P53  with  MRP1,
ecause  their  parallel  increase  is  frequent.  It  was  demon-
trated  that  P53  wild-type  suppressed  MRP1  promoter.  These
ypotheses  are  corroborated  by  our  data,  because  we  always
btained  high  expression  of  MRP1  and  P53.  According  to
hese  authors  P53  was  mutated  in  all  patterns.68
RB  expression  was  lower  in  micropapillary  pattern,  which
lso  explained  a  more  aggressive  phenotype  because  free
2F  activates  transcription  of  genes  related  with  tumor  pro-
ression.
TTF1  was  connected  with  P53  and  HER2  in  lung  can-
er  and  some  authors  relate  this  protein  with  initiation
nd  progression  in  lung  carcinogenesis.19,23 The  relation
etween  TTF1  and  HER2  was  observed  between  solid  and
A/lepidic  patterns,  because  both  gene  expression  was
igher  in  BA/lepidic  pattern  than  in  solid.
onclusions
emale  adenocarcinoma  patients  were  more  frequently  non-
mokers  and  diagnosed  in  earlier  stages,  with  higher  ERCC1
xpression  involved  in  DNA  repair.
Advanced  stages  (IIA  and  IIIA)  of  adenocarcinomas
howed  higher  Ki67,  APC,  ERCC1  expressions  and  lower  TTF1
xpression  reﬂecting  a  more  aggressive,  mitotically  active
nd  less  differentiated  adenocarcinoma  and  eventually  a
on-TRU  adenocarcinoma.
There  was  generally  higher  expression  of  the  products  of
enes  studied  in  the  adenocarcinomas  compared  to  normal
djacent  cells  reinforcing  their  importance  in  lung  adeno-
arcinoma  carcinogenesis.
There  were  two  speciﬁc  gene  expressions  with  differ-
nces  between  patterns,  HER2  and  TTF1  that  interfere  with
ene  transcription.  Papillary  and  solid  patterns  revealed
ess  TTF1  expression,  identical  to  normal  tissue  exhibiting
 non-TRU/bronchial  phenotype.  At  the  other  end  acinar,
A/lepidic  and  micropapillary  showed  higher  TTF1  expres-
ion.  Solid  pattern  revealed  also  lower  HER2  and  higher  EGFR
nd  ERCC1  (this  compared  to  papillary)  expression.  Papillary
howed  higher  HER2  and  lower  ERCC1  expressions.  Adeno-
arcinomas  showed  higher  TTF1  expression  (type  TRU)  in
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268  
cinar,  BA/lepidic  and  micropapillary  patterns,  micropapil-
ary  with  higher  RB  expression,  acinar  with  lower  ERCC1  and
igher  EGFR.  Ciclin  D1  seems  to  have  more  importance  in
cinar  and  BA/lepidic  patterns  than  in  micropapillary.
ERCC1  protein  expression  in  micropapillary,  solid  and
A/lepidic  patterns  indicates  DNA  repair  and  in  acinar  and
apillary  patterns  there  was  lower  expression.  BCL2  was
verexpressed  in  all  patterns,  suggesting  that  there  is  inhi-
ition  of  apoptosis.  MRP-1and  LRP  were  overexpressed  in  all
atterns  and  it  is  important  to  further  analyze  these  proteins
or  a  better  understanding  of  the  response  to  therapy.
By  hierarchical  clustering  test  we  highlight  papillary
attern  as  the  most  different  pattern  followed  by  solid
attern;  acinar  and  BA/lepidic  patterns  are  most  alike.
sing  PCA  analysis  we  realized  that  acinar,  micropapillary
nd  BA/lepidic  patterns  are  the  most  alike,  so  we  made
hree  clusters  of  patterns:  papillary,  solid  and  micropapil-
ary/acinar/lepidic  (BA).
Furthers  studies  are  needed  in  order  to  interpret  these
esults  regarding  therapeutic  response  in  advanced  staged
ronchial-pulmonary  carcinomas.
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